Medical and Medicare-Paid Pharma and Cancer genetic tests

For Medical and Medicare Paid Pharma and Cancer genetic tests in the USA , contact Connie at or text 408-854-1883

Medicare coverage of genetic services. Under Medicare’s guidelines, BRCA1 and BRCA2 genetic testing is covered for people with: A personal history of breast cancer, with one or more of the following: … a close relative with a known BRCA1 or BRCA2 gene mutation.

Medicare coverage of genetic services

Under Medicare’s guidelines, BRCA1 and BRCA2 genetic testing is covered for people with:

  1. A personal history of breast cancer, with one or more of the following:
    • diagnosed at or before age 45, with or without family history
    • diagnosed at or before age 50 or two breast primaries, with 1 or more close blood relative(s) with breast cancer diagnosed at or before age 50 or 1 or more close blood relative(s) with ovarian cancer/fallopian tube/primary peritoneal cancer
    • two breast primaries when first breast cancer diagnosis occurred prior to age 50
    • diagnosed at any age, with 2 or more close blood relatives with breast and/or epithelial ovarian/fallopian tube/primary peritoneal cancer, at any age
    • close male blood relative with breast cancer
    • personal history of epithelial ovarian/fallopian tube/primary peritoneal cancer
    • of a certain ethnicity associated with higher mutation frequency, (eg, founder populations of Ashkenazi Jewish, Icelandic, Swedish, Hungarian or other) no additional family history required
    • a close relative with a known BRCA1 or BRCA2 gene mutation
  2. Personal history of epithelial ovarian/fallopian tube/primary peritoneal cancer.
  3. Personal history of male breast cancer.

Medicare operates on a regional system in which Medicare Area Contractors (MACs) manage the provision of health services for a specific jurisdiction. In the spring of 2015, four MACs expanded their coverage to better align their services with National Comprehensive Cancer Network (NCCN) guidelines in a number of important areas, including:

  • Expanding coverage of genetic testing for individuals who have or had cancer consistent with hereditary cancer syndromes, including men diagnosed with prostate cancer and men and women diagnosed with pancreatic cancer,
  • Coverage of multigene testing panels if more than one mutation may be indicated, and
  • Clarification of the BRCA testing policy for use of the targeted therapyLynparza (olaparib).

It is important to note that these policy changes apply only to states covered by the four MACs:
Arkansas, Arizona, California, Hawaii, Idaho, Kentucky, Montana, Nevada, North Carolina, North Dakota, Ohio, Oregon, South Carolina, South Dakota, Utah, Virginia, Washington, West Virginia and Wyoming

Medicare does not currently cover the cost of genetic testing in individuals who do not have a personal history of cancer.

How can we help our doctors understand our bodies

When health consumers communicate all important health information to doctors, health solutions can be found and matched to the person’s health care needs. Communicating to doctors thoroughly removes the guess work and backed up my diagnostics tests, each health journey can be personalized.

Happy doctor’s day! May all our doctors take care of their health too and always be there for us. May God’s light energy shine upon all doctors always.

Connie Dello Buono

How to lower your lab or hospital bills?

My son was told by One Medical to use the cheaper Lab services for $100 for his blood test while others use the internet to some other lab tests.

For hospital bills, go home early with a caregiver or do only necessary lab and hospital surgeries if possible.

Learn how to avoid emergencies and preventive health.


Get a leg up with these seven ways to negotiate your medical bills.

  1. Learn to Spot Common Medical Billing Errors. …
  2. Go Into a Procedure Knowledgeable of Fees. …
  3. Ask If You Qualify for Discounts. …
  4. Familiarize Yourself With Health Care Mumbo Jumbo. …
  5. Visit the Hospital’s Billing Department. …
  6. Be Polite, But Not a Pushover.

Medical Bills: How to Negotiate the Price of Your Medical Bills | Money
People also ask

How to Get Your Hospital Bill Reduced or Even Eliminated

Your first stop should be the hospital at which you received treatment. You may be able to negotiate with the billing department or settle on a lower amount owed. The worst thing you can do is ignore your medical bills only to have them sent to collections. You want to do everything in your power to avoid that.

7 Tips For Fighting And Paying A Big Hospital Bill – Forbes

Sep 17, 2013 – If you get a four-figure, five-figure or six-figure hospital bill, what should you do? … (MORE: 6 Ways to Negotiate Lower Doctor Bills). And that’s …

Slash Your Medical Bills: 7 Ways to Haggle : MBAA

Haggling with your hospital or dickering with your doctor to lower your medical bills might feel, well, unseemly. But with health care costs pinching the typical …

Medical Bills: How to Negotiate the Price of Your Medical Bills | Money › Everyday Money › Health Care

Jun 29, 2015 – Get a leg up with these seven ways to negotiate your medical bills. Learn to Spot Common Medical Billing Errors. Go Into a Procedure Knowledgeable of Fees. Ask If You Qualify for Discounts. Familiarize Yourself With Health Care Mumbo Jumbo. Visit the Hospital’s Billing Department. Be Polite, But Not a Pushover.

5 Expert Tips for Negotiating Your Medical Bills | For Better | US News

Oct 16, 2014 – How to reduce a large medical bill or help get it covered by insurance. … Medical billsare negotiable, both with the hospital and your insurance …

Reducing Hospital Bills – The Dollar Stretcher

Can you negotiate hospital bills? When it comes to reducing hospital bills, these tips can show you how to negotiate a lower hospital bill. /

How to Reduce a $10,400 Medical Bill To $2400 With a 5 Minute … › Personal Finance

Recently we came across an amazing thread on Reddit in which a person describes their incredible reduction in a medical bill. It reads something like this.

How to Negotiate Medical Bills – The Balance › Money Hacks › Frugal Living › Beauty & Health Care

Sep 25, 2016 – Have lots of medical bills? … tactics described in steps 1 and 2 to negotiate a lowerpayment. … They’ll be much more likely to work with you, if the bill isn’t delinquent. 3. … Don’t stop with your doctor’s fees and hospital bills.

5 Ways to Reduce Your Medical Bills – Health › Home › Your Healthcare Guide

Oct 11, 2013 – If you are thinking about negotiating a hospital bill, however, consider hiring a professional advocate, since hospital bills are considerably more …

How to negotiate your hospital bills | Fox News

Jul 29, 2015 – Opening a huge medical bill after a hospital stay can be enough to make you … prompting a petition signed by 117 oncologists to lower costs.

Un-medicated 92 yr old with Dementia and unnecessary tests

Un-medicated 92 yr old with Dementia

Some seniors forgo over medication to no medication and are thriving at home. With common remedies for arthritis from massage oil (ginger, turmeric), nutrition to supplementation.

Unnecessary tests

Approximately $200 billion is spent every year on healthcare services in the U.S. that provide little value to patients. A Health Affairs study published in April found only a 4% decrease in low-value back imagining 2.5 years after the Choosing Wisely campaign launched. Another study published in JAMA Internal Medicine of seven Choosing Wisely recommendations found only two recommendations had “modest” decreases in usage.

The extensive use of low-value services persists even as the healthcare industry has rallied in support of the Choosing Wisely campaign. Nearly 80 medical societies are now part of the campaign and 500 recommendations on ways to curb overuse of healthcare services have been issued. Many health systems have also implemented Choosing Wisely principles at their organizations.

Despite efforts by stakeholders, progress to curb low-value care is bogged down by flawed approaches and stubborn cultural norms that encourage waste, according to the report.

“What we’ve learned is that it’s just really hard to change practice,” said Dr. Eve Kerr, one of the study’s authors and a professor in the department of internal medicine at the University of Michigan. “Medical professionals have been practicing one way for a long time and patients expect that kind of practice to change the paradigm,” Kerr said. “That doesn’t happen in five years.”

Physicians feel pressure to do unnecessary testing and other services because they don’t want to be hit with a malpractice suit. Other physicians feel they should abide by patient requests for more services to preserve the physician-patient relationship.

MRI contrast agent can damage the kidneys of patients who has cancer already and are terminally ill

Gadolinium-contrast toxicity in patients with kidney disease – NCBI

by MA Perazella – ‎2008 – ‎Cited by 98 – ‎Related articles

Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Gadolinium is widely employed as a contrast agent for magnetic resonance imaging (MRI) and has generally been considered to be safe.

Toxicity of MRI and CT contrast agents. – NCBI

by KM Hasebroock – ‎2009 – ‎Cited by 121 – ‎Related articles

Expert Opin Drug Metab Toxicol. 2009 Apr;5(4):403-16. doi: 10.1517/17425250902873796 . Toxicity ofMRI and CT contrast agents. Hasebroock KM(1), Serkova …

Symptoms associated with Gadolinium Toxicity « Gadolinium Toxicity

Symptoms are generally experienced at an acute level shortly after having a contrast MRI and at a chronic level for years following their last contrast MRI.

Gadolinium Toxicity « shedding light on the effects of retained …

As patients affected by Gadolinium Toxicity from contrast MRIs, we have … first realizes that thecontrast agent they received for an MRI may be the cause of their …

Toxicity of Gadolinium Deposition from MRI Contrast Agents …

Jan 8, 2016 – A recent review article by Ramalho et al summarizes the literature on gadolinium-basedcontrast agents or GBCAs that are administered for …

Left in the Brain: Potentially Toxic Residue from MRI… — ProPublica

Jun 11, 2015 – Left in the Brain: Potentially Toxic Residue from MRI Drugs … As ProPublica has reported, contrast agents like Omniscan had been on the …

Study raises questions about the safety of MRI contrast agent; authors …

Apr 6, 2016 – A comprehensive review of the known and potential risks of gadolinium toxicity commonly used as contrast agent in MRI scanning has been …

MRI Gadolinium Toxicity – Home | Facebook

shedding light on the effects of retained gadolinium from Contrast MRI … MRI Gadolinium Toxicityshared MRI Gadolinium Contrast Awareness’s post.

Gadolinium Toxicity From MRI Scans – Dr L Wilson

Gadolinium is a toxic metal that is used as a contrast medium to visualize the body tissues better during an MRI scan. Gadolinium is injected into the body before …


Connie’s comments:

We decided to not subject our father from chemo and radiation in his last stage of lung cancer. My client with pacreatic cancer have to be subjected to MRI every day at a learning hospital in the bay area. He died on his last week at the hospital.

Another client is still on many medications, in hospice care at home as his kidneys are only functioning 20% of the time.

Be ready with your power of attorney, living will, medical health directives and other estate planning documents. We can refer you to estate lawyers in the bay area.


Your health care is your choice and your health is your privilege. Do take care of your body. When I do not have medical insurance, I go to farmer’s market and take care of my body and spend money on quality supplements at:

ageloc youth 99

Molecular cancer screen at a distance

cancer screen.JPG

Molecular biomarkers are independent of the presence of a detectable tumor mass or even the detection of intact transformed cells. Instead, they represent detection at a distance, using molecular signals in blood or excretia to indicate the presence of a cancer or pre-invasive lesion. These molecular biomarkers fall into four groups (Table 1).

Some are products of the neoplastic process that are shed by the tumors, such as mutated or hypermethylated DNA (‘carcinogenesis markers’). Others are molecular species generated by the host response to the cancer (‘response biomarkers’). Examples include antibodies, protein degradation products,12 and acute phase reactants.13

A third group of biomarkers, like blood in stool or PSA in serum, are released in abnormal amounts as a result of the anatomical or metabolic disruption associated with a tumor (‘released biomarkers’).

The final group of molecular markers comprises factors associated with or supporting the underlying carcinogenesis (‘risk biomarkers’). Examples are high estradiol levels in relation to breast cancer or markers of human papilloma virus in relation to cervical cancer.

These classes of biomarkers will probably behave differently in early detection. Carcinogenesis markers are likely to be relatively specific for invasive or pre-invasive neoplasia, as they are essentially found only in on-going carcinogenesis.

Testing for PSA or blood in stool has already shown that released biomarkers can be non-specific: pathology other than cancer often leads to their release into blood and stool respectively.

Risk biomarkers are often abnormal in individuals without cancer; these are really risk factors, markers of cancer risk rather than markers of cancer itself.

Typically only a minority of individuals with the risk factors actually develop the associated disease.

Thus, just as benign masses can mimic tumors or obscure cancers in anatomical screening, pathological and metabolic processes will affect the specificity of molecular screening, especially if it is not based on carcinogenesis markers. PSA provides many examples: hemodilution of PSA levels in obese men,14, 15distortion of levels by medication,14 and increases in levels from prostatitis.16 Inflammation – a risk factor for cancer in many organs — may be a particular problem as it shares molecular mediators with carcinogenesis.

One is that the tests are convenient and safe – typically requiring only the donation of blood, urine or stool. Measuring these molecular biomarkers does not involve tests that deliver radiation, a visit to the clinic, or unpleasant procedures as is needed for colonoscopy. Thus, the use of molecular biomarkers is likely to improve the uptake of screening by the general population and make repeated testing practical and affordable. This would increase the sensitivity of the screening process, and correspondingly increase the chances of detecting early cancers. However, it would also increase the potential for false positives, with the adverse downstream consequence of unnecessary diagnostic follow-ups.

Another advantage of molecular biomarkers is that they can easily be combined into panels using mathematical techniques such as logistic models or recursive partitioning to enhance sensitivity and specificity. Such combinations might be less susceptible to measurement artifacts than the individual markers. Also, the quantitative nature of many molecular markers means that they can potentially be personalized, using age, sex and race-specific norms, for example.

Pre-malignant lesions

Since the molecular defects of early cancer are often similar to those of intraepithelial neoplasia,40molecular screening for cancers will likely identify substantial numbers of pre-invasive lesions. In organs such as the colorectum and cervix, these can be removed relatively easily to reduce risk of future cancer. Excision of pre-invasive lesions identified in less accessible tissues, such as the pancreas, entails considerable morbidity. It may not be clear what should be done to address the increased risk of invasive cancer, particularly as the natural history of these screen-detected lesions may not be well characterized.

Some risk biomarkers and some reaction biomarkers (such as antibodies) might remain in the abnormal range even after the responsible lesions are completely removed. For example, long-term hormonal patterns that promoted carcinogenesis presumably would continue, and some antibodies generated by a tumor may persist. Markers that do revert to normal after successful treatment could be used to follow disease recurrence and progression, as PSA (for prostate cancer) CEA (for colorectal cancer) and CA-125 (for ovarian cancer) are used now. Here again, advanced anatomical detection may aid the molecular screen to locate recurrent neoplasia that is not otherwise evident. Ideally, the validation of molecular screening markers would include study of their behavior as markers of disease progression after excision of the tumors that are detected.

In some organs, it may even be a challenge to find the cancers indicated by molecular biomarkers.

Some of the cancers detected may not need to be treated.

Do you want to know more about a molecular cancer screen many years before an actual cancer can be detected? Email as need at least 25,000 people who wanted to be cancer screen early 20yrs before a real threat appears and another tests to determine the molecular age of your cells.